Key result
Plasma cardiotrophin-1 levels were higher in hypertensive and diabetic patients than controls and correlated with arterial, cardiac, and early renal target organ damage.
Why the study?
Does plasma cardiotrophin-1 correlate with target organ damage and cardiovascular risk in patients with hypertension and type 2 diabetes?
Observational (n=384)
Does plasma cardiotrophin-1 correlate with target organ damage and cardiovascular risk in patients with hypertension and type 2 diabetes?
Plasma cardiotrophin-1 is strongly associated with target organ damage in hypertension and diabetes, suggesting its potential as a biomarker for cardiovascular injury and risk.
Answers are grounded in this paper and cite their sources.
CT-1 levels were associated with target organ damage; leaves open biomarker utility pending prospective validation.
The search for biomarkers of hypertension and diabetes-induced damage to multiple target organs is a priority. We analyzed the correlation between plasma cardiotrophin-1 (CT-1), a chemokine that participates in cardiovascular remodeling and organ fibrosis, and a wide range of parameters currently used to diagnose morphological and functional progressive injury in left ventricle, arteries, and kidneys of diabetic and hypertensive patients, in order to validate plasma levels of CT-1 as clinical biomarker.This is an observational study with 93 type 2-diabetic patients, 209 hypertensive patients, and 82 healthy controls in which we assessed the following parameters: plasma CT-1, basal glycaemia, systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), left ventricular hypertrophy (LVH by electrocardiographic indexes), peripheral vascular disease (by pulse wave velocity-PWV, carotid intima-media thickness-C-IMT, and ankle-brachial index-ABI), and renal impairment (by microalbuminuria, albumin/creatinine urinary ratio, plasma creatinine concentrations, and glomerular filtration rate).Hypertensive or diabetic patients have higher plasma CT-1 than control patients. CT-1 positively correlates with basal glycaemia, SBP, DBP, PP, LVH, arterial damage (increased IMT, decreased ABI), and early renal damage (microalbuminuria, elevated albumin/creatinine ratio). CT-1 also correlates with increased 10-year cardiovascular risk. Multiple linear regression analysis confirmed that CT-1 was associated with arterial injury assessed by PWV, IMT, ABI, and cardiac damage evaluated by Cornell voltage duration product.Increases in plasma CT-1 are strongly related to the intensity of several parameters associated to target organ damage supporting further investigation of its diagnostic capacity as single biomarker of cardiovascular injury and risk and, possibly, of subclinical renal damage.
No takes yet. Share an insight, caveat, or question.
Gamella-Pozuelo et al. (2015) conducted an observational in Hypertension and Type 2 Diabetes (n=384). Plasma cardiotrophin-1 (CT-1) vs. Healthy controls was evaluated on Correlation with target organ damage (LVH, arterial damage, renal impairment) and cardiovascular risk. Plasma cardiotrophin-1 levels were higher in hypertensive and diabetic patients than controls and correlated with arterial, cardiac, and early renal target organ damage.
Synapse has enriched 10 related papers. Consider them for comparative context: